Meeting
2020 ASCO Virtual Scientific Program
Duration of FOLFOX adjuvant chemotherapy in high-risk stage II and stage III colon cancer with deficient DNA mismatch repair.
Authors
Zehua Wu
Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Zehua Wu , Huabin Hu , Chao Wang , Yan Huang , Yanhong Deng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Epidemiology/Outcomes
Citation
J Clin Oncol 38: 2020 (suppl; abstr 4075)
DOI
10.1200/JCO.2020.38.15_suppl.4075
Abstract #
4075
Poster Bd #
67
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Early versus conventional adjuvant chemotherapy in stage III colon cancer: A multicenter, randomized, open-label, phase 3 trial.
First Author: Soo Yeun Park
Poster
2023 ASCO Annual Meeting
A randomized trial of consolidation-targeted adjuvant therapy with encorafenib and cetuximab versus usual care for patients with stage II/III BRAF V600E colon cancer: Alliance for Clinical Trials in Oncology A022004.
First Author: Rona Yaeger
Poster
2021 ASCO Annual Meeting
Association of HER2 expression with pathologic features and prognosis in stage II and III colon cancer.
First Author: Zehua Wu
Poster
2020 ASCO Virtual Scientific Program
![Tumor-infiltrating lymphocytes and tumor budding refine prognostication in patients with low- and high-risk stage III colon cancers (NCCTG N0147)[Alliance].](https://d201v5jt9ylckg.cloudfront.net/258/14746/188424/188424_poster_pv.jpg)
Tumor-infiltrating lymphocytes and tumor budding refine prognostication in patients with low- and high-risk stage III colon cancers (NCCTG N0147)[Alliance].
First Author: Dan Sha